Oral mucosal injury in oncology patients: Perspectives on maturation of a field

Oral Diseases

Volumn 21, Issue 2, 2015, Pages 133-141

  Peterson, De ^a,b   Srivastava, R ^b,c   Lalla, Rv ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Cancer therapy; Clinical practice guidelines; Mucosal injury; Mucositis

Indexed keywords

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL PRACTICE; DISEASE SEVERITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MOLECULAR INTERACTION; MOUTH MUCOSA; ORAL MUCOSITIS; PATHOLOGY; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMS BIOLOGY; ADVERSE EFFECTS; COMPLICATION; INJURIES; MOLECULARLY TARGETED THERAPY; NEOPLASMS; ORAL ULCER; STOMATITIS;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; MOUTH MUCOSA; NEOPLASMS; ORAL ULCER; STOMATITIS;

EID: 84923116484     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12167     Document Type: Review

References (59)

1. Al-Dasooqi N, Keefe DM (2011). Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemother 57: 43-53.
2. Al-Dasooqi N, Bowen JM, Gibson RJ et al (2011). Animal models of mucositis: implications for therapy. J Support Oncol 9: 161-168.
3. Al-Dasooqi N, Sonis ST, Bowen JM et al (2013). Emerging evidence on the pathobiology of mucositis. Support Care Cancer doi:10.1007/s00520-013-1810-y [Epub ahead of print].
4. Alterovitz G, Tuthill C, Rios I, Modelska K, Sonis S (2011). Personalized medicine for mucositis: Bayesian networks identify unique gene clusters which predict the response to gamma-D-glutamyl-L-tryptophan (SCV-07) for the attenuation of chemoradiation-induced oral mucositis. Oral Oncol 47: 951-955.
5. Bowen JM, Gibson RJ, Keefe DM (2011). Animal models of mucositis: implications for therapy. J Support Oncol 9: 161-168.
6. Brennan MT, Lalla RV, Schubert MM, Peterson DE (2012). Oral toxicity. In Perry MC, Doll DC, Freter CE eds. Perry's The Chemotherapy Source Book. 5th edn. Lippincott Williams & Wilkins: PA, USA, pp. 112-138.
7. Calantog A, Hallajian L, Nabelsi T et al (2013). A prospective study to assess in vivo optical coherence tomography imaging for early detection of chemotherapy-induced oral mucositis. Lasers Surg Med 45: 22-27.
8. Chen P, Lingen M, Sonis ST et al (2011). Role of AMP-18 in oral mucositis. Oral Oncol 47: 831-839.
9. Cheng KK, Lee V, Li CH et al (2013). Impact of oral mucositis on short-term clinical outcomes in paediatric and adolescent patients undergoing chemotherapy. Support Care Cancer 21: 2145-2152.
10. Colley HE, Eves PC, Pinnock A, Thornhill MH, Murdoch C (2013). Tissue-engineered oral mucosa to study radiotherapy-induced oral mucositis. Int J Radiat Biol doi:10.3109/09553002.2013.809171 [Epub ahead of print].
11. Cotrim AP, Yoshikawa M, Sunshine AN et al (2012). Pharmacological protection from radiation +/- cisplatin-induced oral mucositis. Int J Radiat Oncol Biol Phys 83: 1284-1290.
12. Deisboeck TS, Zhang L, Yoon J, Costa J (2009). In silico cancer modeling: is it ready for prime time? Nature Rev Clin Oncol 6: 34-42.
13. Diaz PI, Dupuy AK, Abusleme L et al (2012). Using high throughput sequencing to explore the biodiversity in oral bacterial communities. Mol Oral Microbiol 27: 182-201.
14. Elting LS, Keefe DM, Sonis ST et al (2008). Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113: 2704-2713.
15. Elting LS, Chang YC, Parelkar P et al (2013). Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer doi:10.1007/s00520-013-1821-8 [Epub ahead of print].
16. Garg MB, Lincz LF, Adler K, Scorgie FE, Ackland SP, Sakoff JA (2012). Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis. Br J Cancer 107: 1525-1533.
17. Gordon Research Conference (2013). Mucosal Health & Disease. Available at: http://www.grc.org/programs.aspx?year=2013&program=mucosal. [accessed on 22 May 2013].
18. Hahn T, Zhelnova E, Sucheston L et al (2010). A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation. Biol Blood Marrow Transplant 16: 801-808.
19. Karr JR, Sanghvi JC, Macklin DN et al (2012). A whole-cell computational model predicts phenotype from genotype. Cell 150: 389-401.
20. Karr JR, Sanghvi JC, Macklin DN et al (2013). WholeCellKB: model organism databases for comprehensive whole-cell models. Nucleic Acids Res 41: D787-D792.
21. Keefe DM, Schubert MM, Elting LS et al (2007). Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109: 820-831.
22. Keefe DM, Sonis ST, Bowen JM (2008). Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs 13: 511-522.
23. Kim KI, Kim JW, Lee HJ et al (2013). Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation. Am J Hematol 88: 107-112.
24. Kreeger PK, Lauffenburger DA (2010). Cancer systems biology: a network modeling perspective. Carcinogen 31: 2-8.
25. Kruser TJ, Rice SR, Cleary KP et al (2013). Acute hematologic and mucosal toxicities in head and neck cancer patients undergoing chemoradiotherapy: a comparison of 3D-CRT, IMRT, and helical tomotherapy. Technol Cancer Res Treat 12: 383-389.
26. Lalla RV (2013). The MASCC/ISOO Mucositis Guidelines Update: introduction to the first set of articles. Support Care Cancer 21: 301-302.
27. Logan RM, Gibson RJ, Sonis ST et al (2007). Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43: 395-401.
28. Logan RM, Stringer AM, Bowen JM et al (2009). Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 63: 239-251.
29. Michelson S, Sehgal A, Friedrich C (2006). In silico prediction of clinical efficacy. Curr Opin Biotechnol 17: 666-670.
30. Miller MM, Donald DV, Hagemann TM (2012). Prevention and treatment of oral mucositis in children with cancer. J Pediatr Pharmacol Ther 17: 340-350.
31. Molina F, Dehmer M, Perco P et al (2010). Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant 25: 1015-1018.
32. Mougeot JL, Bahrani-Mougeot FK, Lockhart PB et al (2011). Microarray analyses of oral punch biopsies from acute myeloid leukemia (AML) patients treated with chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112: 446-452.
33. Mougeot JL, Mougeot FK, Peterson DE et al (2013). Use of archived biopsy specimens to study gene expression in oral mucosa from chemotherapy-treated cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol 115: 630-637.
34. Multnatl Assoc Supp Care Cancer & Intl Soc Oral Oncol (2013). Available at: http: www.mascc.org. [accessed on 22 May 2013].
35. Natl Cancer Inst PDQ® (2013). Oral complications of chemotherapy and head/neck radiation. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/HealthProfessional/page5. [accessed on 22 May 2013].
36. Pawson T, Warner N (2007). Oncogenic re-wiring of cellular signaling pathways. Oncogene 26: 1268-1275.
37. Peterson DE, Lalla RV (2010). Oral mucositis: the new paradigms. Current Opin Oncol 22: 318-322.
38. Peterson DE, Bensadoun RJ, Lalla RV et al (2011). Supportive care treatment guidelines: value, limitations, and opportunities. Semin Oncol 38: 367-373.
39. Peterson DE, Keefe DM, Sonis ST (2012). New frontiers in mucositis. In: Govindan R, ed. 2012 ASCO Educational Book. Am Soc Clin Oncol: Alexandria, VA, USA, pp. 545-551.
40. Pilotte AP, Hohos MB, Polson KM et al (2011). Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors. Clin J Oncol Nurs 15: E83-E89.
41. Reynolds C, Spira AI, Gluck L et al (2013). Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial. Invest New Drugs 31: 1330-1338.
42. Rini BI (2010). New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 16: 1348-1354.
43. Rubenstein EB, Peterson DE, Schubert M et al (2004). Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100: 2026-2046.
44. Sonis ST (2007). Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol (9 Suppl 4): 3-11.
45. Sonis ST (2009). Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45: 1015-1020.
46. Sonis ST (2010a). Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. Core Evid 4: 199-205.
47. Sonis ST (2010b). New thoughts on the initiation of mucositis. Oral Dis 16: 597-600.
48. Sonis ST (2011). Oral mucositis. Anticancer Drugs 22: 607-612.
49. Sonis S, Haddad R, Posner M et al (2007). Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 43: 289-300.
50. Sonis S, Antin J, Tedaldi M, Alterovitz G (2013). SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral Dis 19: 721-727.
51. Stringer AM (2013). Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients 5: 1488-1499.
52. Swierniak A, Kimmel M, Smieja J (2009). Mathematical modeling as a tool for planning anticancer therapy. Eur J Clin Pharmacol 625: 108-121.
53. Tarca AL, Carey VJ, Chen XW, Romero R, Draghici S (2007). Machine learning and its applications to biology. PLoS Comput Biol 3: e116.
54. Thiele I, Swainston N, Fleming RM et al (2013). A community-driven global reconstruction of human metabolism. Nat Biotechnol 31: 419-25.
55. Vodovotz Y, Csete M, Bartels J, Chang S, An G (2008). Translational systems biology of inflammation. PLoS Comput Biol 4: e1000014.
56. Yang K, Ma W, Liang H et al (2007). Dynamic simulations on the arachidonic acid metabolic network. PLoS Comput Biol 3: e55.
57. Yasuda M, Kato S, Yamanaka N et al (2013). 5-HT3 receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. Br J Pharmacol 168: 1388-1400.
58. Yip KY, Cheng C, Gerstein M (2013). Machine learning and genome annotation: a match meant to be? Genome Biol 14: 205. [Epub ahead of print].
59. Zheng C, Cotrim AP, Sunshine AN et al (2009). Prevention of radiation-induced oral mucositis after adenoviral vector-mediated transfer of the keratinocyte growth factor cDNA to mouse submandibular glands. Clin Cancer Res 15: 4641-4648.